<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03775187</url>
  </required_header>
  <id_info>
    <org_study_id>UX023-EAP</org_study_id>
    <nct_id>NCT03775187</nct_id>
  </id_info>
  <brief_title>Expanded Access to Burosumab</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <brief_summary>
    <textblock>
      Individual patient expanded access requests may be considered for patients who have no other&#xD;
      treatment options&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Expanded access may provide access for treatment prior to approval by the local regulatory&#xD;
      agency. For full details, please visit the link provided.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>X-linked Hypophosphatemia</condition>
  <condition>Tumor-Induced Osteomalacia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Burosumab</intervention_name>
    <other_name>UX023</other_name>
    <other_name>CrysvitaÂ®</other_name>
    <other_name>KRN23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Early Access</last_name>
    <phone>1-415-483-8800</phone>
    <email>EarlyAccess@ultragenyx.com</email>
  </overall_contact>
  <link>
    <url>https://www.ultragenyx.com/our-purpose/supporting-access-for-patients/?#investigational-therapies</url>
    <description>Access to Investigational Therapies / Requesting Access</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <keyword>XLH</keyword>
  <keyword>TIO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Osteomalacia</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

